VEGFA and metastatic colorectal cancer: FMT in combination with tislelizumab (an anti-programmed death receptor 1 (PD-1) monoclonal immunoglobulin G-4 antibody [90]) and fruquintinib (a novel potent anti-vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor [91]) has also shown promise for refractory metastatic colorectal cancer [92].